Lichen simplex chronicus when systemic agents have not controlled pruritus and scratching
Lichen simplex chronicus is sustained by a persistent itch–scratch cycle that drives progressive lichenification. When systemic pharmacotherapy fails to achieve adequate control of pruritus and scratching behaviour, a structured next step is required.
Prior treatment line — insufficient response
The previous step involved systemic agents — including gabapentin, pregabalin, doxepin, mirtazapine, SSRIs, methotrexate, cyclosporine, dupilumab, and nemolizumab. The goal of that line — reduction of pruritus and scratching behaviour — was not adequately achieved. This protocol defines the approach taken after that failure.
Next-step approach (partial overview)
At this stage the protocol turns to procedural interventions targeting refractory lichenified skin. Several physical and device-based modalities are considered — the specific selection criteria, order of use, and clinical details are set out in the full structured regimen.
Clinical goals
Reduction of pruritus and flattening or clearance of lichenified plaques.
References
DOI: 10.1007/s40257-025-00979-z
- Cryosurgery, which involves freezing and destroying abnormal skin cells, helps alleviate pruritus by flattening the thickened plaques characteristic of LSC and disrupting the itch-scratch cycle by reducing cutaneous nerve endings.
- A 2022 meta-analysis of clinical studies found that adding liquid nitrogen cryotherapy to conventional topical treatment significantly improved LSC outcomes without increasing adverse effects.
- Serial electrobrasion was successfully used to treat a 67-year-old male with refractory lichenified plaques on his lower extremities.
- Ablative fractional CO2 laser (AFXL) is emerging as a therapy to reduce thickness and induce regeneration in lichenified skin.
- Narrowband UVB (NB-UVB) phototherapy significantly reduces pruritus with minimal side effects.
- High-frequency focused ultrasound is a novel device therapy mentioned in recent literature for vulvar LSC.
- Botulinum toxin type A (BoNTA) has also shown promise in the treatment of recalcitrant localized pruritus in LSC.
View source ↗